VANCOUVER, June 16 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader
in the development of receptor targeted fusion proteins, today announced that
it has appointed Dr. Alexander R. Giaquinto to its Board of Directors. Dr.
Giaquinto is currently the Senior Vice President of Regulatory Affairs and
Quality Assurance for Regado Biosciences Inc. and acts as an independent
consultant to several pharmaceutical companies. He brings to Protox over 35
years of experience in the pharmaceutical industry, including 30 years at
Schering-Plough where he was most recently Senior Vice President of Worldwide
Regulatory Affairs and prior to his retirement reported directly to the CEO
overseeing Global Compliance.
"We are delighted to welcome Dr. Giaquinto to the Board of Directors,"
said Frank Holler, Chairman of the Board of Protox. "He is a respected U.S and
international regulatory veteran who brings unique insight and exceptional
industry knowledge to Protox. His extensive regulatory expertise will add
significant depth to our Board and will provide invaluable leadership and
guidance as we continue to advance our novel drug candidates towards
At Schering-Plough, Dr. Giaquinto was instrumental in establishing the
development and regulatory strategies for the approvals of over 100 New Drug
Applications (NDAs) and Supplements, Biologic License Applications (BLAs) and
Abbreviated NDAs, including Eulexin for prostate cancer and Temodal for brain
cancer. Dr. Giaquinto was a founding member of the Steering Committee of the
International Conference of Harmonization (ICH) where he introduced the
concept of the Common Technical Document (CTD). He has chaired the Regulatory
Affairs Coordinating Committee of the Pharmaceutical Research and
Manufacturers of America (PhRMA). He is currently on the Board of Directors
for SemBioSys Genetics, Endoceutics and Biothera, as well as a member of the
Scientific Advisory Boards for Allozyne Inc. and EndoCeutics.
Dr. Giaquinto earned a Bachelor of Science in Pharmacy from St. John's
University and a Ph.D. in Pharmaceutics from the University of Connecticut.
Leaving the Protox Board is Nitin Kaushal, who has served as a Director
since 2004. "On behalf of the company, I would like to thank Nitin for his
commitment and counsel to Protox and wish him continued success," added Mr.
Protox Therapeutics is a leader in advancing novel, receptor targeted
fusion proteins. Two novel drug candidates derived from the company's
INxin(TM) and PORxin(TM) platforms are being developed in three clinical
programs. Protox's lead program, PRX302 (PORxin), is currently being studied
in a Phase 2b placebo controlled trial to treat benign prostatic hyperplasia
(BPH or enlarged prostate). Final positive Phase 2a results treating BPH
patients were released at the end of 2008 and a phase 2a clinical trial
evaluating PRX302 for the treatment of localized prostate cancer is ongoing. A
Phase 2a clinical trial evaluating PRX321 (INxin) for the treatment of primary
brain cancer has been completed and the drug has received Fast Track
Designation and Orphan Drug Status from the US FDA and EMEA. Protox is also
collaborating with the U.S. National Institutes of Health (NIH) on a research
program focused on the discovery of next generation fully human targeted
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Protox'
current beliefs as well as assumptions made by and information currently
available to Protox and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Protox in its public securities filings; actual
events may differ materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
For further information:
For further information: James Beesley, Senior Director, Investor
Relations, Protox Therapeutics, (604) 484-0975,
email@example.com; Michael Moore, Investor Relations, Equicom
Group, (416) 815-0700 x 241, firstname.lastname@example.org